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yelin-associated glycoprotein (MAG) is expressed
in periaxonal membranes of myelinating glia where
it is believed to function in glia–axon interactions
by binding to a component of the axolemma. Experiments
involving Western blot overlay and coimmunoprecipitation
demonstrated that MAG binds to a phosphorylated neuronal
isoform of microtubule-associated protein 1B (MAP1B)
expressed in dorsal root ganglion neurons (DRGNs) and
axolemma-enriched fractions from myelinated axons of
brain, but not to the isoform of MAP1B expressed by glial
cells. The expression of some MAP1B as a neuronal plasma
membrane glycoprotein (Tanner, S.L., R. Franzen, H. Jaffe,
M
 
and R.H. Quarles. 2000. 
 
J. Neurochem.
 
 75:553–562.),
further documented here by its immunostaining without
cell permeabilization, is consistent with it being a binding
partner for MAG on the axonal surface. Binding sites for a
MAG-Fc chimera on DRGNs colocalized with MAP1B on
neuronal varicosities, and MAG and MAP1B also colocalized
in the periaxonal region of myelinated axons. In addition,
expression of the phosphorylated isoform of MAP1B was
increased signiﬁcantly when DRGNs were cocultured with
MAG-transfected COS cells. The interaction of MAG with
MAP1B is relevant to the known role of MAG in affecting
the cytoskeletal structure and stability of myelinated axons.
 
Introduction
 
The localization of myelin-associated glycoprotein (MAG)* in
periaxonal membranes of myelin-forming oligodendrocytes
and Schwann cells (SCs) suggests that it functions in glia/axon
communication by interacting with a component(s) of the
axonal surface membrane (for review see Quarles, 1997).
Myelin formation is relatively normal during development
of MAG-null mice (Li et al., 1994; Montag et al., 1994),
but there is degeneration of myelinated axons of peripheral
nerve as the mice age (Fruttiger et al., 1995; Yin et al.,
1998). The axonal degeneration, which involves decreased
caliber and cytoskeletal abnormalities such as reduced
phosphorylation and closer packing of neurofilaments (Yin
et al., 1998), suggests that the interaction of MAG with a
component on the axon is required for normal long term
maintenance of myelinated axons. In addition, MAG can
promote or inhibit neurite outgrowth in vitro (for review
see Cai et al., 2001), also demonstrating that MAG affects
neuronal properties. However, little is known about the
molecular mechanisms by which MAG affects axonal
structure, particularly its neuronal binding partner(s).
MAG has been shown to interact with a variety of neuronal
glycoproteins (DeBellard and Filbin, 1999; Strenge et al.,
1999) and gangliosides (Collins et al., 1999) based on its lec-
tin specificity for 2,3-linked sialic acid (Kelm et al., 1994).
However, there is evidence indicating that sialic acid–binding
may reflect a docking mechanism and that a separate peptide-
binding site in MAG is crucial for its effects on neurons (Tang
et al., 1997). In this report, we describe the binding of MAG
to proteins of neuronal membrane preparations from the
peripheral and central nervous systems, respectively, that
would be expected to contain physiological MAG binding
partners, i.e., membranes from dorsal root ganglion neurons
(DRGNs) and axolemma-enriched fractions (AEFs) from my-
elinated axons of brain. In both cases, MAG bound primarily
to a high molecular weight protein that was identified as mi-
crotubule-associated protein 1B (MAP1B). A previous report
from our laboratory (Tanner et al., 2000) and new findings in
this paper demonstrate that some MAP1B is expressed as a
plasma membrane glycoprotein in neurons, supporting the
concept that MAP1B is an axonal binding partner for MAG.
 
Address correspondence to Richard Quarles, Lab of Molecular and Cel-
lular Neurobiology, NINDS, NIH, Bldg. 49, Rm. 2A28, 49 Convent
Dr., MSC 4440, Bethesda, MD 20892-4440. Tel.: (301) 496-6647. Fax:
(301) 496-8244. E-mail: quarlesr@ninds.nih.gov
*Abbreviations used in this paper: AEF, axolemma-enriched fraction;
DRGN, dorsal root ganglion neuron; MAG, myelin-associated glycopro-
tein; mAb, monoclonal antibody; MAP1B, microtubule-associated pro-
tein 1B; SC, Schwann cell.
Key words: axons; cytoskeleton; microtubule-associated proteins; myelin-
associated glycoprotein; neuroglia 
894 The Journal of Cell Biology 
 
|
 
 
 
Volume 155, Number 6, 2001
 
Results and discussion
 
MAG interacts with neuronal MAP1B
 
To identify MAG-binding proteins in axonal membranes
that would be expected to contain the MAG binding part-
ner, total proteins were solubilized from cultured DRGNs
and isolated AEFs. Western blots of the proteins were incu-
bated with affinity-purified native MAG. MAG bound most
strongly to a high molecular weight protein above the 250
kD standard in both DRGNs and AEFs (Fig. 1 A). This pro-
tein was identified initially as MAP1B by mass spectral anal-
ysis of the band excised from SDS gels in a manner similar to
that described previously (Tanner et al., 2000). When blots
on which MAG binding had been demonstrated were
stripped and immunostained for MAP1B, the MAG-binding
component corresponded to the MAP1B bands (Fig. 1 A).
The interaction of MAG with MAP1B was also demon-
strated by coimmunoprecipitation (Fig. 1 B). Isolated AEFs
contain MAG because of the presence of periaxonal oligoden-
droglial membranes in addition to the axolemma (DeVries et
al., 1983). MAG was immunoprecipitated from the AEF with
rabbit anti-MAG antiserum, and the immunoprecipitates were
fractionated by SDS-PAGE and immunostained for MAP1B.
MAP1B was in the immunoprecipitate obtained with anti-
MAG antiserum but not in the one obtained with normal rab-
bit serum (Fig. 1 B, left). MAP1B is phosphorylated both by
proline-directed serine/threonine kinases and casein kinase II
(for review see Gordon-Weeks and Fischer, 2000). The
broader appearance of the MAP1B band in the whole AEF in
the left lane is due to the fact that the AA6 monoclonal anti-
body (mAb) recognizes all isoforms of MAP1B whether or not
they are phosphorylated (Fig. 1 B, left), whereas the MAP1B
that coimmunoprecipitated with MAG appeared to corre-
spond to phosphorylated MAP1B with higher apparent molec-
ular weight. This interpretation is supported by reactivity of
the coimmunoprecipitated MAP1B with mAb SMI-31 to
phosphorylated MAP1B (Fig. 1 B, right).
The presence of MAP1B in AEFs isolated from my-
elinated axons, which had been described previously (Sa-
pirstein et al., 1992), is consistent with it being a physiologi-
cal axonal binding partner for MAG. We confirmed the
well-known decrease in the total amount of MAP1B in brain
during maturation (Gordon-Weeks and Fischer, 2000), but
a high concentration of MAP1B is retained in the AEF even
from adult brains when it could not be detected in whole
brain homogenate (Fig. 1 C). This enrichment of MAP1B
in the periaxonal compartment of adult myelinated axons
supports the possibility that it has a functional role in glia–
axon interactions at this site.
 
Colocalization of MAP1B and MAG-binding sites on 
the surface of neurons
 
When the binding of MAG to MAP1B was first observed, it
seemed that MAP1B was unlikely to be a physiological bind-
ing partner for MAG on the axonal surface because it is gener-
ally thought to be an intracellular cytoskeletal component
(Gordon-Weeks and Fischer, 2000). However, MAP1B had
been proposed to be a membrane glycoprotein based on a hy-
drophobic amino acid sequence that could be a transmem-
brane domain, potential sites for N-linked glycosylation and
its role as a substrate for ecto-kinases (Muramoto et al., 1994).
Subsequent studies in our laboratory supported this hypothesis
that some MAP1B is expressed as a membrane glycoprotein
on the surface of neurons (Tanner et al., 2000). Our results
pointed to the expression of MAP1B as a type II transmem-
brane glycoprotein in which the COOH terminus and glyco-
sylation sites are extracellular and the microtubule binding do-
mains are in the neuronal cytoplasm. Immunostaining of
DRGNs showed that MAP1B is concentrated in varicosities
distributed along the neurites (Tanner et al., 2000). New evi-
dence for the expression of MAP1B as a surface protein on
neurons is shown in Fig. 2 A, demonstrating a similar localiza-
tion of MAP1B at neuronal varicosities whether or not the
neurons were permeabilized before immunostaining. The sur-
face immunostaining was observed both with mAb AA6 (A1)
and with the polyclonal antiserum recognizing amino acid se-
quence 2056–2070 (unpublished data), which is in the extra-
cellular domain of MAP1B, according to its model as a trans-
membrane glycoprotein (Tanner et al., 2000).
To determine if MAG-binding sites on neurons colocalize
with MAP1B, cultured DRGNs were incubated with a
MAG-Fc chimera (Fig. 2 B). MAG-Fc–binding sites (B2)
were discontinuously distributed along the neurites in a
punctate pattern in accordance with the report of Turnley
and Bartlett (1999). The binding pattern was similar to the
immunostaining for MAP1B (B1), and the overlapping sig-
nals in B3 show the colocalization of MAG-binding sites
with MAP1B on neuronal varicosities. There was no bind-
ing of human-Fc chimera used as a negative control (Fig. 2
C). Also, there was no MAG-Fc binding when MAP1B was
blocked previously with polyclonal antiserum to MAP1B
(Fig. 2 D), demonstrating the specificity of the interaction.
Fig. 2 E shows double immunostaining of a section of my-
elinated peripheral nerve for MAP1B and MAG. MAP1B
Figure 1. Interaction of MAG with MAP1B. (A) Binding of MAG to 
MAP1B on Western blots. A blot of the proteins (50  g) in the AEF 
and DRGNs was overlayed with MAG, and the bound MAG was 
detected by immunostaining with the 513 mAb (left). The blot was 
then stripped and immunostained with the AA6 mAb to MAP1B 
(right). (B) Coimmunoprecipitation of MAP1B with MAG from AEF. 
Total proteins (50  g) in the AEF and immunoprecipitates (IP) 
obtained from 50  g total protein with rabbit polyclonal anti-MAG 
antiserum (MAG) or normal rabbit serum (Con) were immuno-
stained for total MAP1B with AA6 (left) and for phosphorylated 
isoforms of MAP1B with SMI31 (right). (C) Enrichment of MAP1B 
in AEF from myelinated axons of adult brain. Western blot of equal 
amounts of protein (30  g) from 14-d-old (P14) and adult rat brain 
homogenates (Hom) and AEFs were immunostained for MAP1B 
with mAb AA6. 
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was enriched at the periphery of axons in the region of the
axolemma, and MAG appeared as rings corresponding to
the periaxonal SC membrane. Colocalization of MAP1B
and MAG, revealed by the overlapping yellow signal, is con-
sistent with an interaction of MAG and MAB1B at the SC-
axon junction in myelinated nerve.
 
Lack of binding of MAG to glial MAP1B
 
Because MAP1B is also expressed by SCs (Ma et al., 1999)
and oligodendrocytes (Vouyiouklis and Brophy, 1993), a
possibility was that the MAG binding to MAP1B represents
a cis interaction within myelinating glia. Fig. 3 A shows that
primary SCs and immortalized S16 SCs express MAP1B,
but it is of lower molecular weight than the primary neu-
ronal isoform and does not react with the SMI-31 antibody
to phosphorylated epitopes in neuronal MAP1B. Ma et al.
(1999) also reported that phosphorylation of MAP1B in
SCs is different from that in neurons. Furthermore, blot
overlay and coimmunoprecipitation experiments with SCs
and oligodendrocytes gave no evidence for an interaction of
MAG with glial MAP1B. For example, Fig. 3 B shows an
overlay experiment in which binding of MAG to the higher
molecular weight form of MAP1B in DRGNs was clearly
demonstrated, but there was no binding to MAP1B of S16
SCs. This appears to be due to a difference in the isoforms
expressed by neurons and SCs, respectively, because the
MAG binding corresponds to the higher molecular weight
phosphorylated MAP1B in neurons, which is not expressed
in SCs (Fig. 3 A, second panel, and B, third panel). Coim-
munoprecipitation experiments also demonstrated the speci-
ficity of the interaction of MAG with neuronal MAP1B
(Fig. 3 C). MAG was in the immunoprecipitate when
MAP1B was immunoprecipitated from the AEF with anti-
MAP1B antiserum. This is the inverse of the experiment
Figure 2. Colocalization of MAG-binding 
sites and MAP1B on the surface of neurons in 
vitro and of MAG and MAP1B in myelinated 
nerves. (A) Similar immunofluorescent 
staining of MAP1B at neuronal varicosities 
of cultured DRGNs by mAb AA6 was 
observed without (A1) or with (A2) prior per-
meabilization with Triton X-100. (B) Double 
immunostaining of cultured embryonic 
DRGNs that had been maintained for 3 h 
in the presence of MAG-Fc chimera. 
Immunostaining for MAG-Fc (FITC) shows 
MAG-binding sites on the neurons (B2), and 
B1 shows the same neuron immunostained 
for MAP1B (Rhodamine). Overlapping red 
and green images result in yellow signals 
(B3), demonstrating the colocalization of 
MAG-Fc–binding sites with MAP1B on 
neuronal varicosities (arrows). (C) Negative 
control for panels B1 and B2. The MAP1B-
positive varicosities (C1) did not bind 
human Fc (C2). (D) Antibody blocking. 
MAG-Fc binding to DRGNs (D1) was 
inhibited when the culture was pretreated 
for 2 h with antiserum to MAP1B sequence 
2056–2070 before adding MAG-Fc (D2) but 
not when the pretreatment was with an 
antibody to synaptophysin (unpublished 
data), a plasma membrane protein similarly 
distributed at varicosities of DRGNs (Tanner 
et al., 2000). (E) Double immunostaining of 
MAP1B and MAG in rat sciatic nerve. These 
localizations of MAP1B (FITC) and MAG 
(Rhodamine) are similar to those shown 
previously in ventral roots (Tanner et al., 
2000), and here we demonstrate their 
colocalization at the glia-axon junction by 
the overlapping yellow signal (arrows). 
Schmidt-Lanterman incisure was strongly 
reactive for MAG (arrowhead). Bars: (A) 
5  m; (B) 3.3  m; (C) 10  m; (D) 10  m; 
(E) 8  m. 
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shown in Fig. 1 B in which coimmunoprecipitation was
with anti-MAG antiserum and further documents the inter-
action between MAG and neuronal MAP1B. Although the
immortalized S16 SC line is differentiated toward myelina-
tion and expresses a substantial amount of MAG (Toda et
al., 1994), there was no MAG coimmunoprecipitated with
MAP1B from S16 SC extracts by the same antiserum.
 
Expression of phosphorylated MAP1B in neurons is 
increased in the presence of MAG
 
When DRGNs were cocultured with MAG-transfected
COS cells, total MAP1B and phosphorylated MAP1B
were increased in comparison to DRGNs cocultured with
mock-transfected COS cells (Fig. 4 A). Densitometry of
Western blots from three separate experiments revealed
that total MAP1B was increased 2.1 
 
 
 
 0.12-fold (
 
p
 
 
 
 
 
0.01) and total phosphorylated MAP1B was increased
1.8 
 
 
 
 0.12-fold (
 
p
 
 
 
  
 
0.05) in the presence of MAG.
Since COS cells do not express MAP1B (Fig. 4 B), these
changes demonstrate that interaction of DRGNs with
MAG causes increased expression of its phosphorylated
MAP1B binding partner.
 
General comments
 
Studies summarized in the Introduction on MAG-null mice
and on the effects of MAG on neurite outgrowth have
pointed to MAG acting as a ligand for an axonal receptor
that affects the cytoskeletal structure of neurons. Here, sev-
eral different methods were used to demonstrate that
MAP1B is a neuronal binding partner for MAG including
blot overlay, coimmunoprecipitation, and colocalization.
MAP1B appears to play roles in neuronal differentiation
(Gordon-Weeks and Fischer, 2000) and axonal formation
(Gonzalez-Billault et al., 2001) by regulating cytoskeletal orga-
nization, but its exact functions remain unclear. Disruption of
MAP1B expression in vivo by gene targeting has generally sup-
ported such roles (Edelmann et al., 1996; Takei et al., 1997;
Meixner et al., 2000). Of particular interest, with regard to the
potential role of MAP1B as a neuronal binding partner for
MAG, is the impaired myelination reported for two of these
mutants (Takei et al., 1997; Meixner et al., 2000).
It is well established that the cytoskeletal structure of axons
is modulated by surrounding myelin sheaths, based on studies
of dysmyelinating mutants and comparisons of myelinated
and nonmyelinated regions of the same axon (Kirkpatrick
and Brady, 1999). For example, the neurofilaments in periph-
eral nerves of Trembler mutants exhibit decreased phosphory-
lation and increased density in comparison to normally my-
elinated nerves. The similar changes observed in MAG-null
mice (Yin et al., 1998) suggest that MAG may be involved in
the molecular mechanism by which myelin affects the axonal
cytoskeleton. Furthermore, the stability of microtubules and
the phosphorylation of several MAPs, including MAP1B, are
decreased in the absence of normal myelin in Trembler mice
(Kirkpatrick and Brady, 1994). Here, we demonstrate that
the expression and phosphorylation of MAP1B are increased
in DRGNs cocultured with MAG-expressing cells. These
findings are all consistent with an effect of MAG on the phos-
phorylation and structure of cytoskeletal elements in the
axon, including MAP1B. Based on the findings reported
here, we hypothesize that a MAG–MAP1B interaction could
provide a structural link between the periaxonal membrane of
Figure 3. Lack of MAG binding to MAP1B of SCss. (A) Western 
blots comparing MAP1B expression in DRGNs, primary SC cultures, 
and immortalized S16 SCs (50  g protein each lane). The left panel 
was stained for total MAP1B with AA6, the middle panel for 
phosphorylated MAP1B (MAP1BP ) with SMI-31, and the right panel 
for total MAP1B with a rabbit antiserum. Arrows point to higher and 
lower molecular weight isoforms of MAP1B. (B) Western blot of a 
MAG overlay experiment similar to Fig. 1 A, showing MAG binding 
(left) to the proteins of AEF and S16 SCs (50  g each). The same blot 
was then stripped and immunostained with AA6 (middle) and SMI31 
(right). (C) Coimmunoprecipitation of MAG with MAP1B. Immuno-
precipitates obtained from 50  g total protein of the AEF (left) and 
100  g total protein of S16 SCs (right) with polyclonal anti-MAP1B 
antiserum (MAP1B) or normal rabbit serum (Con) were electropho-
resed, blotted, and immunostained for MAG with B11F7. Other 
immunostained blots (unpublished data) confirmed the presence of 
MAG in the S16 cells and comparable amounts of MAP1B in the 
immunoprecipitates from AEF and S16 SCs, respectively.
Figure 4. Increased MAP1B expression in DRGNs cocultured 
with MAG-expressing cells. (A) Representative blots of cocultures 
(50  g protein) of DRGNs with mock-transfected COS cells or 
MAG-expressing COS cells immunostained for total MAP1B 
(AA6 mAb), phosphorylated MAP1B (MAP1BP
  and
 SMI-31 mAb), 
and  -actin. (B) A blot of AEF and COS cells (each 50  g protein) 
immunostained for MAP1B (AA6). 
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the myelin-forming cell and the axonal cytoskeleton, thereby
contributing to the known capacity of myelin to affect the
structure and stability of myelinated axons.
 
Materials and methods
 
Cell culture and subcellular fractionation
 
DRGNs from 16-d-old fetal rats were cultured as described previously
(Tanner et al., 2000). 5 d later, neurons were solubilized in PBS containing
complete protease inhibitor cocktail (Roche Molecular Biochemicals),
phosphatase inhibitors (50 mM NaF and 100 
 
 
 
M Na
 
3
 
VO
 
4
 
), and 1% Triton
X-100 (PPi buffer). The proteins of primary SC cultures and immortalized
S16 SCs (Toda et al., 1994) were solubilized in the same way. The heavy
AEF was isolated from myelinated axons of rat brain (DeVries, 1981).
 
Antibodies. 
 
Mouse mAbs to MAP1B were AA6 that reacts with all iso-
forms (Sigma-Aldrich) and SMI-31 that is specific for mode I phosphorylated
epitopes (Sternberger). Rabbit polyclonal antisera to synthetic peptides cor-
responding to MAP1B sequences included one to the NH
 
2
 
 terminus from Dr.
P. Brophy (University of Edinburgh, Edinburgh, Scotland) and another to
amino acids 2056–2070 raised by Zymed Laboratories. Antibodies to MAG
included an mAb 513 to native MAG (Poltorak et al., 1987) and an mAb
(B11F7) and rabbit polyclonal antisera raised in our laboratory.
 
Purification of native MAG and binding to proteins 
on Western blots
 
Nondenatured MAG was purified from adult rat brain myelin by immu-
noaffinity with the 513 mAb by a procedure similar to that described by
Poltorak et al. (1987) using the Immunopure Protein G IgG Orientation Kit
from Pierce Chemical Co. MAG binding to the antibody beads was at 4
 
 
 
C
for 16 h, and it was eluted with a pH 11.5 solution of 50 mM diethanola-
mine and 5 mM 
 
 
 
-octylglucoside. Proteins in membrane fractions were
separated by SDS-PAGE and transferred to nitrocellulose membranes. The
blots were incubated overnight at 4
 
 
 
C in a blocking reagent (from the DIG
Glycan Differentiation Kit; Roche) and washed twice in TBS (pH 7.5). After
rinsing once in TBS containing 1 mM MgCl
 
2
 
, 1 mM MnCl
 
2
 
 and 1mM CaCl
 
2
 
blots were incubated for 3 h at room temperature with 10 
 
 
 
g per ml of pu-
rified MAG in the same buffer. After washing with TBS, bound MAG was
detected by immunostaining (overnight at 4
 
 
 
C) with the 513 mAb followed
by peroxidase labeled anti–mouse IgG (ICN Biomedicals) and ECL (NEN
Life Science Products).
 
Coimmunoprecipitation
 
MAG was immunoprecipitated from the proteins of AEFs (50 
 
 
 
g solubi-
lized in PPi buffer) with polyclonal anti-MAG antiserum overnight at 4
 
 
 
C
followed by protein A Sepharose (Amersham Pharmacia Biotech) for 1 h at
4
 
 
 
C. MAP1B was immunoprecipitated similarly from the AEF and S16 SC
protein extracts with the polyclonal antibody to its NH
 
2
 
 terminus. Immu-
noprecipitates were washed three times in PPi buffer, solubilized, and frac-
tionated by SDS-PAGE. After transfer to blots and blocking, coimmunopre-
cipitated proteins were detected by immunostaining with ECL.
 
Immunostaining and localization of MAG-binding sites
 
Cultured DRGNs fixed with 2% paraformaldehyde and 0.1% glutaralde-
hyde were immunostained for MAP1B either without permeabilization or
with permeabilization by exposure to 1% Triton X-100 in PBS for 10 min.
After blocking for 30 min in 10% normal goat serum (NGS) in PBS, cells
were incubated for 1 h with primary antibodies to MAP1B, rinsed with
PBS, and incubated with appropriate Texas red–coupled secondary anti-
bodies (Jackson ImmunoResearch Laboratories). Sections of rat sciatic
nerve were immunostained for MAG and MAP1B as described previously
(Tanner et al., 2000).
For localization of MAG-binding sites on cultured DRGNs, fixation was
with 1% paraformaldehyde in PBS. After blocking in 2% FBS and 2% NGS in
PBS, the cells were incubated either with a MAG-Fc chimera protein (5 
 
 
 
g/
ml; R&D Systems) or with human-Fc protein (5 
 
 
 
g/ml; ICN Biomedicals)
for 3 h at 4
 
 
 
C. After three PBS washes, FITC-coupled anti–human Fc antibody
was applied for 1 h. The cells were blocked again as above either with or
without prior treatment with ice-cold methanol and then incubated with poly-
clonal antibody to MAP1B followed by rhodamine-coupled anti–rabbit IgG.
 
Protein analysis of DRGNs cocultured with MAG-expressing 
COS cells
 
COS-7 cells were stably transfected by lipofectamine reagent (GIBCO-BRL)
with either 2 
 
 
 
g L-MAGpcDNA3.1 (provided by M. Filbin, Hunter Col-
lege, New York, NY) or 2 
 
 
 
g pcDNA3.1 (Invitrogen) without the L-MAG
insert (mock transfected). E17 DRGNs were plated on 6-well collagen-
coated plates at a density of 5 
 
 
 
 10
 
5
 
 cells/well and maintained in defined
medium (DMEM 
 
 
 
 N2 
 
 
 
 2% FBS 
 
  
 
100 ng/ml NGF) for 5 d. DRGNs were
then seeded onto 10
 
5
 
 COS-7 cells for 4 d. Cell lysates were fractionated by
SDS-PAGE, blotted, and immunostained for MAP1B with ECL. Densitome-
try was with NIH Image software (version 1.6), and statistical comparisons
were by a two-tailed paired 
 
t
 
 test.
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